Bristol Myers Squibb Breyanzi gets USFDA nod for Relapsed or Refractory Mantle Cell Lymphoma Ruchika Sharma31 May 2024 2:15 PM ISTPrinceton: Bristol Myers Squibb has announced the U.S. Food and Drug Administration (FDA) has granted approval for Breyanzi (lisocabtagene...
Bristol Myers Squibb gets USFDA accelerated nod for Breyanzi as CAR T Cell Therapy for adults with relapsed or refractory chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Susmita Roy15 March 2024 12:32 PM ISTPrinceton: Bristol Myers Squibb has announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval of...
Liso-cel cost effective second-line treatment for common form of lymphoma Dr. Kamal Kant Kohli2 Jan 2024 6:00 AM ISTLisocabtagene maraleucel (liso-cel), a CAR T-cell therapy, is a cost effective second line treatment for relapsed and refractory (hard to treat)...
Bristol Myers Squibb gets European Commission nod for CAR T Cell therapy Breyanzi for relapsed or refractory large B-cell lymphoma after one prior therapy Ruchika Sharma5 May 2023 2:30 PM ISTBreyanzi is a CD19-directed CAR T cell therapy with a 4-1BB costimulatory domain, which enhances the expansion and persistence of the CAR T cells.
Bristol Myers Squibb gets positive EMA Committee opinion for Breyanzi for Relapsed or Refractory Large B-cell Lymphoma after one prior therapy Ruchika Sharma2 April 2023 10:00 AM ISTBreyanzi is a CD19-directed CAR T cell therapy with a 4-1BB costimulatory domain, which enhances the expansion and persistence of the CAR T cells.
Bristol Myers Squibb bags USFDA nod for CAR T Cell Therapy Breyanzi Ruchika Sharma26 Jun 2022 4:00 PM ISTBreyanzi, a differentiated CAR T cell therapy, is made from a patient's own T cells, which are collected and genetically reengineered to become CAR T...
USFDA extends action date for Bristol Myers Squibb Lisocabtagene Maraleucel (liso-cel) Ruchika Sharma10 May 2020 12:15 PM ISTLiso-cel is an investigational chimeric antigen receptor (CAR) T-cell therapy designed to target CD19
